1. Ureteropelvic Junction Obstruction
Hashim Hashim, Christopher R.J. Woodhouse 
European Urology Supplements 
Volume 11, Issue 2, Pages (April 2012)
DOI: /j.eursup
Copyright © 2012 European Association of Urology Terms and Conditions

2. Fig. 1
Type 1 renogram.
European Urology Supplements  , 25-32DOI: ( /j.eursup )
Copyright © 2012 European Association of Urology Terms and Conditions

3. Fig. 2
Type 2 renogram of left kidney (40mg frusemide administered intravenously at 15min).
European Urology Supplements  , 25-32DOI: ( /j.eursup )
Copyright © 2012 European Association of Urology Terms and Conditions

4. Fig. 3
Type 3a renogram bilaterally (5mg frusemide administered intravenously at 15min).
European Urology Supplements  , 25-32DOI: ( /j.eursup )
Copyright © 2012 European Association of Urology Terms and Conditions

5. Fig. 4
Outcome of treated patients with ureteropelvic junction obstruction (UPJO) based on diethylenetriamine penta-acetic acid (DTPA) results.
APD=anteroposterior diameter.
European Urology Supplements  , 25-32DOI: ( /j.eursup )
Copyright © 2012 European Association of Urology Terms and Conditions

6. Fig. 5
Suggested algorithm for the treatment of ureteropelvic junction obstruction.
APD=anteroposterior diameter; DMSA=dimercaptosuccinic acid; MAG3=mercaptoacetyltriglycine; MCUG=micturating cystourethrogram; SFU=Society of Fetal Ultrasound; USS=ultrasonographic scan.
European Urology Supplements  , 25-32DOI: ( /j.eursup )
Copyright © 2012 European Association of Urology Terms and Conditions